We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Verona Pharma Plc | VRP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 55.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 55.00 | 55.00 |
| Top Posts |
|---|
Posted at 06/2/2023 09:58 by haff1 Not good from a TA perspective: lowering highs and lowering lows....the graph is indicating a fall!! So no change in VRP expectaions.... |
Posted at 10/8/2022 22:29 by timbo003 >>>HTGLooking at the chart it looks as if the all time high occurred during Oct 2009 and was about 17p/old ordinary share or 850p/new ordinary share |
Posted at 09/8/2022 19:48 by haroldthegreat Tim perhaps you should remove the LSE VRP charts ? Looks like that the shares have flat lined . Today they have been given a shot of Viagra but like Viagra the effect on the share price is waning after a few hours ! |
Posted at 01/12/2021 09:55 by haff1 I've been in VRP for over 10 years and it's yet to stand up to its original potential. It's been increditably slow and has seen constant devaluation of the share price from the start.... |
Posted at 10/6/2021 14:35 by haff1 now this is what we've been waiting for for years.....this is very good news for VRP.. |
Posted at 12/3/2021 16:56 by haff1 NASDAQ has recold highs...but VRP falls!....no surprize there then...... |
Posted at 03/3/2021 23:37 by drradcliffe Yes I know. Once they get Ensifentrine through the phase 3 trials, approved by the FDA and launched commercially, we'll still do very well. The stock will be valued at a much higher figure than it ever would have been on the London market. I've only stuck with the investment because the phase 2 clinical trial results look good enough for a commercial product. I don't think the price will do much this year, but next year should see serious growth if everything goes according to plan. Like anyone else who converted from VRP, I'm still up 50%. |
Posted at 21/9/2020 09:51 by drradcliffe You might not have to sell them. You can have ADS holdings in an ISA, and your broker could convert them whilst the AIM VRP shares are still trading. See Appendix A on the Verona announcement. |
Posted at 08/9/2020 09:51 by goggin In Trump world, if this has a sniff of success, then it will come to market and that will be the que for forward momentum. £7 within 2 years and who knows what after that - VRP vs Bleech ha ha, which one do you think will get approval to treat covid-19? |
Posted at 28/7/2020 12:29 by bbonsall Yes, all very frustrating! However, there could be more chance of a partnership announcement now VRP has a lot of cash behind it. There may be that sort of announcement that could come before next year’s trial results. Also, we might find that VRP are involved in helping Covid 19 patients with residual lung damage. There may be many different types of possible news to come In the near future.Also, according to a poster on another board, institutions seem to be increasing holdings. “Access Bio have bought 10.7% of the shares, R A Capital have bought 9.9% and Orbi Med have increased their % from 9.5 to 11% , New Enterprise increased from 9.3 to 9.9% of the shares -all in the last couple of weeks. These corporate investors wouldnt be taking on so much if theres a risk.” |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
